Episode 143: GU Podcast (2020): The Expanding Role Of Immune Checkpoint Inhibitors In MIBC And NMIBC

The Expanding Role of Immune Checkpoint Inhibitors in MIBC and NMIBC
At the conclusion of this activity, participants will be able to:
1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer.
2. Describe the mechanism of action of immunotherapy regimens.
3. Identify and manage the adverse events related to these agents.

This educational series is supported by independent educational grants from:

• Astellas
• AstraZeneca
• Bristol Myers Squibb
• Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
• Merck
• Pfizer, Inc
• Sanofi Genzyme
• UroGen Pharma, Inc.

CME Available: auau.auanet.org/node/29831